comprehensive -WSS

comprehensive

author：fashion 2025-10-01 23:06:02 - browse：8723

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Obamacare plans could cover weight loss drugs

WSS

A new drug could help frostbite victims avoid its ravages

New study raises questions about niacin and heart health

A new drug could help frostbite victims avoid its ravages

Profiling embryos to choose those with higher IQs is almost a reality

Medicare Advantage enrollment hits roughly 33.4 million

FDA warns medical device makers about rise in fabricated data

hotspot

comprehensive

explore

How to save PrEP access — and even expand it

Weight loss drugs aren’t covered by Obamacare. That may change

BioMarin wins approval for gene therapy to treat hemophilia A

American taxpayers paid $1.8 trillion in health care costs in 2022

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA warns medical device makers about rise in fabricated data

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

focus

Physician assistants need a new name. Here's what it should be

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Merck to acquire Harpoon Therapeutics for $680 million

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Secretariat’s lessons for human medicine

leisure time

hotspot

knowledge

focus